Design Therapeutics (DSGN) Non Operating Income (2020 - 2026)

Design Therapeutics has disclosed Non Operating Income across 7 years of filings, most recently posting $2.4 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $2.4 million, down 5.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 million (down 0.6% YoY), and the FY2025 annual result was $9.7 million, up 4.57% from the prior year.
• Non Operating Income came in at $2.4 million for Q1 2026 at Design Therapeutics, up from $2.2 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $5.7 million in Q4 2023 to a low of $105000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.4 million (2023), against an average of $2.4 million.
• Across the five-year window, Non Operating Income soared 7731.58% in 2022 and plunged 53.43% in 2024, its largest moves.
• Design Therapeutics' Non Operating Income stood at $2.1 million in 2022, then surged by 175.93% to $5.7 million in 2023, then slumped by 53.43% to $2.6 million in 2024, then retreated by 17.1% to $2.2 million in 2025, then rose by 10.02% to $2.4 million in 2026.
• The last three Non Operating Income figures came in at $2.4 million (Q1 2026), $2.2 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.